Listed

Chemed Corp: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on Apr 28, 2025 and accepted by EDGAR at Apr 28, 2025, 09:06 ET.

Share

Management's discussion and analysis

As filed, 28,826 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world. We continue to monitor macroeconomic trends and uncertainties such as inflation, the effects of recently implemented tariffs, and the potential imposition of modified or additional tariffs, which may have adverse effects on net sales and profitability. Based on preliminary analysis of the potential effects of the announced tariffs and these other factors, we do not expect a material negative effect on our net sales or profitability for the remainder of fiscal year 2025. However, we are continuing to evaluate these factors and their potential effects as well as our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts for fiscal year 2026 planning. Economic pressures including the challenges of high inflation and the effects of increased tariffs may negatively affect our net sales and profitability in the future.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended March 31, 2025 2024
Service revenues and sales $646,943 $589,233
Net income $71,757 $65,017
Diluted EPS $4.86 $4.24
Adjusted net income $83,074 $79,831
Adjusted diluted EPS $5.63 $5.20
Adjusted EBITDA $121,692 $114,622
Adjusted EBITDA as a % of revenue 18.8% 19.5%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 30-31.

For the three months ended March 31, 2025, the increase in consolidated service revenues and sales was driven by a 15.1% increase at VITAS and by a 1.8% increase at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of a 11.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 3.2%. Acuity mix shift negatively impacted revenue growth by 112-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 112-basis points. The increase in service revenues at Roto-Rooter was driven by an increase in excavation and water restoration offset by a decrease in plumbing and drain cleaning.

On April 17, 2024, VITAS completed the purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc d/b/a/ Covenant Care (“Covenant”) for an aggregated purchase price of $85.0 million in cash.

Revenue for the Covenant acquisition for the first three months of 2025 was approximately $11.5 million to $12.5 million and this translated to net income of approximately $1.8 million to $2.0 million. Adjusted EBITDA in the quarter attributed to Covenant is between $2.5 million and $2.7 million.

The pro forma revenue and earnings for the Company for the three months ended March 31, as if the Covenant acquisition made in 2024 was completed on January 1, 2024 are as follows (in thousands, except per share data):

Three months ended March 31, 2025 2024
Service revenues and sales $646,943 $604,081
Net income $71,757 $68,679
Earnings per share $4.91 $4.54
Diluted earnings per share $4.86 $4.48

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2024 to March 31, 2025 include the following:

A $114.7 million increase in accounts receivable due to the reclassification of the OAS deposit of $47.0 million. Other significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $57.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.

A $47.3 million decrease in other assets primarily related to the reclassification of the OAS deposit from a long-term receivable to accounts receivable.

A $3.8 million increase in lease right of use asset due to lease renewals. This resulted in a similar increase in the lease liability accounts.

A $3.5 million increase in accounts payable due to timing of payments.

A $30.7 million decrease in income taxes payable due to timing of payments.

A $32.2 million decline in accrued compensation due primarily to the payment of 2024 bonuses in the first quarter of 2025.

Net cash provided by operating activities decreased $51.8 million from March 31, 2024 to March 31, 2025. The main drivers are a increase of $72.8 million due to accounts receivable offset by a $20.4 million decline in accounts payable.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.

Commitments and Contingencies

On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2025, the interest rate is SOFR plus 100 basis points. The 2022 Credit Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and/or term loan by an additional $250.0 million.

We have issued $45.5 million in standby letters of credit as of March 31, 2025, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of March 31, 2025, we have approximately $404.5 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2025 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

Results of Operations

Three months ended March 31, 2025 versus 2024 - Consolidated Results

Our service revenues and sales for the first quarter of 2025 increased 9.8% versus services and sales revenues for the first quarter of 2024. Of this increase, a $53.4 million increase was attributable to VITAS, and a $4.3 million increase at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Three months ended March 31, 2025 2024 Increase/(Decrease) Percent
Routine homecare $351,566 $304,860 15.3
General inpatient 34,022 30,303 12.3
Continuous care 24,637 24,169 1.9
Other 5,344 4,084 30.9
Subtotal 415,569 363,416 14.4
Medicare cap adjustment (2,325) (2,375) 2.1
Room and board - net (3,525) (2,944) (19.7)
Implicit price concessions (2,319) (4,090) 43.3
Net revenue $407,400 $354,007 15.1
Roto-Rooter
Drain cleaning $59,542 $61,621 (3.4)
Plumbing 46,059 48,098 (4.2)
Excavation 64,239 58,618 9.6
Other 186 244 (23.8)
Subtotal - short term core 170,026 168,581 0.9
Water restoration 54,163 46,678 16.0
Independent contractors 18,362 19,616 (6.4)
Outside franchisee fees 1,424 1,491 (4.5)
Other 4,895 6,015 (18.6)
Gross revenue 248,870 242,381 2.7
Implicit price concessions (9,327) (7,155) (30.4)
Net revenue 239,543 235,226 1.8
Total Revenues $646,943 $589,233 9.8

Days of care at VITAS during the quarters were as follows:

Three months ended March 31, 2025 2024 Increase/(Decrease) Percent
Routine homecare 1,632,569 1,447,912 12.8
Nursing home 307,108 283,158 8.5
Respite 9,995 7,752 28.9
Subtotal routine homecare and respite 1,949,672 1,738,822 12.1
General inpatient 29,704 26,645 11.5
Continuous care 22,620 24,037 (5.9)
Total days of care 2,001,996 1,789,504 11.9

The increase in service revenues at VITAS is comprised primarily of a 11.9% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 3.2%. Acuity mix shift negatively impacted revenue growth by 112-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 112-basis.

The decrease in drain cleaning revenues for the first quarter of 2025 versus 2024 is attributable to a 3.2% increase in price and service mix offset by a 6.6% decrease in job count. The decrease in plumbing revenues for the first quarter of 2025 versus 2024 is attributable to a 3.3% decrease in price and service mix shift and a 0.9% decrease in job count. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues. As a result, excavation revenues increased 9.6% and water restoration revenues increased 16.0%. Contractors operations decreased 6.4%.

The consolidated gross margin was 33.5% in the first quarter of 2025 as compared with 34.6% in the first quarter of 2024. On a segment basis, VITAS’ gross margin was 23.2% in the first quarter of 2025 essentially equal to first quarter of 2024. The Roto-Rooter segment’s gross margin was 50.9% for the first quarter of 2025 as compared with 51.9% in the first quarter of 2024.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended March 31, 2025 2024
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $103,760 $98,418
Long-term incentive compensation 2,657 9,121
Impact of market value adjustments related to assets held in deferred compensation trusts (830) 8,334
Total SG&A expenses $105,587 $115,873

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2025 were up 5.4% when compared to first quarter of 2024 due mainly to normal salary increases and an increase in variable selling expenses.

Other income – net comprise (in thousands):

Three months ended March 31, 2025 2024
Interest income $2,076 $4,243
Market value adjustment on assets held in deferred compensation trusts (830) 8,334
Other (1) -
Total other income - net $1,245 $12,577

We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. Chemed invests excess cash in money market funds holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended March 31, 2025 2024
Income tax provision calculated at the statutory federal rate $20,092 $17,742
State and local income taxes 4,187 2,961
Stock compensation tax benefits (463) (3,297)
Other--net 101 2,062
Income tax provision $23,917 $19,468
Effective tax rate 25.0% 23.0%

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

Roto-Rooter Three months ended March 31, 2025 2024
Amortization of reacquired franchise agreements $(1,806) $(1,804)
Corporate
Stock option expense (7,621) (7,555)
Long-term incentive compensation (2,353) (3,415)
Severance arrangement - (5,337)
Excess tax benefits on stock compensation 463 3,297
Total $(11,317) $(14,814)

Three months ended March 31, 2025 versus 2024 - Segment Results

Net income/(loss) for the first quarter of 2025 versus the first quarter of 2024 by segment (in thousands):

Three months ended March 31, 2025 2024
VITAS $50,030 $43,970
Roto-Rooter 39,944 40,853
Corporate (18,217) (19,806)
$71,757 $65,017

After-tax earnings as a percent of revenue at VITAS in the first quarter of 2025 was 12.3% as compared to 12.4% in the first quarter of 2024.

Roto-Rooter’s after-tax earnings as a percent of revenue in the first quarter of 2025 was 16.7%, as compared to 17.4% in the first quarter of 2024.

After-tax Corporate expenses for the first quarter of 2025 decreased 8.0% when compared to the first quarter in 2024 due primarily to a $6.3 million decrease in stock-based compensation offset by a $2.2 million decrease in interest income and a $2.8 million decrease in excess tax benefits on stock compensation.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(in thousands)(unaudited)

2025 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $407,400 $239,543 $- $646,943
Cost of services provided and goods sold 312,807 117,723 - 430,530
Selling, general and administrative expenses 26,538 62,649 16,400 105,587
Depreciation 5,196 8,237 12 13,445
Amortization 26 2,546 - 2,572
Other operating expense/(income) 64 (13) - 51
Total costs and expenses 344,631 191,142 16,412 552,185
Income/(loss) from operations 62,769 48,401 (16,412) 94,758
Interest expense (48) (132) (149) (329)
Intercompany interest income/(expense) 5,296 3,930 (9,226) -
Other income—net 48 10 1,187 1,245
Income/(expense) before income taxes 68,065 52,209 (24,600) 95,674
Income taxes (18,035) (12,265) 6,383 (23,917)
Net income/(loss) $50,030 $39,944 $(18,217) $71,757
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(9,091) $(9,091)
Long-term incentive compensation - - (2,657) (2,657)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Total $- $(2,352) $(11,748) $(14,100)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(7,621) $(7,621)
Long-term incentive compensation - - (2,353) (2,353)
Amortization of reacquired franchise agreements - (1,806) - (1,806)
Excess tax benefits on stock compensation - - 463 463
Total $- $(1,806) $(9,511) $(11,317)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2024

(in thousands)(unaudited)

2024 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $354,007 $235,226 $- $589,233
Cost of services provided and goods sold 271,896 113,231 - 385,127
Selling, general and administrative expenses 23,792 61,260 30,821 115,873
Depreciation 5,166 8,108 13 13,287
Amortization 26 2,495 - 2,521
Other operating expense 7 85 - 92
Total costs and expenses 300,887 185,179 30,834 516,900
Income/(loss) from operations 53,120 50,047 (30,834) 72,333
Interest expense (46) (117) (262) (425)
Intercompany interest income/(expense) 5,194 3,442 (8,636) -
Other income—net 29 22 12,526 12,577
Income/(expense) before income taxes 58,297 53,394 (27,206) 84,485
Income taxes (14,327) (12,541) 7,400 (19,468)
Net income/(loss) $43,970 $40,853 $(19,806) $65,017
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- $- $(9,026) $(9,026)
Severance arrangement - - (5,337) (5,337)
Long-term incentive compensation - - (3,784) (3,784)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Total $- $(2,352) $(18,147) $(20,499)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(7,555) $(7,555)
Severance arrangement - - (5,337) (5,337)
Long-term incentive compensation - - (3,415) (3,415)
Amortization of reacquired franchise agreements - (1,804) - (1,804)
Excess tax benefits on stock compensation - - 3,297 3,297
Total $- $(1,804) $(13,010) $(14,814)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2025 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $50,030 $39,944 $(18,217) $71,757
Add/(deduct):
Interest expense 48 132 149 329
Income taxes 18,035 12,265 (6,383) 23,917
Depreciation 5,196 8,237 12 13,445
Amortization 26 2,546 - 2,572
EBITDA 73,335 63,124 (24,439) 112,020
Add/(deduct):
Intercompany interest expense/(income) (5,296) (3,930) 9,226 -
Interest income (49) (10) (2,017) (2,076)
Stock option expense - - 9,091 9,091
Long-term incentive compensation - - 2,657 2,657
Adjusted EBITDA $67,990 $59,184 $(5,482) $121,692
Chemed
For the three months ended March 31, 2024 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $43,970 $40,853 $(19,806) $65,017
Add/(deduct):
Interest expense 46 117 262 425
Income taxes 14,327 12,541 (7,400) 19,468
Depreciation 5,166 8,108 13 13,287
Amortization 26 2,495 - 2,521
EBITDA 63,535 64,114 (26,931) 100,718
Add/(deduct):
Intercompany interest expense/(income) (5,194) (3,442) 8,636 -
Interest income (29) (22) (4,192) (4,243)
Stock option expense - - 9,026 9,026
Severance arrangement - - 5,337 5,337
Long-term incentive compensation - - 3,784 3,784
Adjusted EBITDA $58,312 $60,650 $(4,340) $114,622

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended March 31, 2025 2024
Net income as reported $71,757 $65,017
Add/(deduct) pre-tax cost of:
Stock option expense 9,091 9,026
Long-term incentive compensation 2,657 3,784
Amortization of reacquired franchise agreements 2,352 2,352
Severance arrangement - 5,337
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (2,320) (2,388)
Excess tax benefits on stock compensation (463) (3,297)
Adjusted net income $83,074 $79,831
Diluted Earnings Per Share As Reported
Net income $4.86 $4.24
Average number of shares outstanding 14,764 15,339
Adjusted Diluted Earnings Per Share
Adjusted net income $5.63 $5.20
Adjusted average number of shares outstanding 14,764 15,339
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

OPERATING STATISTICS Net revenue ($000) Three Months Ended March 31, 2025 2024
Homecare $351,566 $304,860
Inpatient 34,022 30,303
Continuous care 24,637 24,169
Other 5,344 4,084
Subtotal $415,569 $363,416
Room and board, net (3,525) (2,944)
Contractual allowances (2,319) (4,090)
Medicare cap allowance (2,325) (2,375)
Total $407,400 $354,007
Net revenue as a percent of total before Medicare cap allowances
Homecare 84.6% 83.9%
Inpatient 8.2 8.3
Continuous care 5.9 6.7
Other 1.3 1.1
Subtotal 100.0 100.0
Room and board, net (0.8) (0.8)
Contractual allowances (0.6) (1.1)
Medicare cap allowance (0.6) (0.7)
Total 98.0% 97.4%
Days of care
Homecare 1,632,569 1,447,912
Nursing home 307,108 283,158
Respite 9,995 7,752
Subtotal routine homecare and respite 1,949,672 1,738,822
Inpatient 29,704 26,645
Continuous care 22,620 24,037
Total 2,001,996 1,789,504
Number of days in relevant time period 90 91
Average daily census (days)
Homecare 18,140 15,911
Nursing home 3,412 3,112
Respite 111 85
Subtotal routine homecare and respite 21,663 19,108
Inpatient 330 293
Continuous care 251 264
Total 22,244 19,665
Total Admissions 18,139 16,911
Total Discharges 17,875 16,170
Average length of stay (days) 118.7 103.9
Median length of stay (days) 16.0 16.0
ADC by major diagnosis
Cerebro 44.7% 43.6%
Neurological 12.4 13.4
Cancer 9.6 10.1
Cardio 16.1 16.1
Respiratory 7.2 7.2
Other 10.0 9.6
Total 100.0% 100.0%
Admissions by major diagnosis
Cerebro 28.4% 27.7%
Neurological 6.5 7.5
Cancer 24.6 24.6
Cardio 15.0 15.6
Respiratory 11.6 10.8
Other 13.9 13.8
Total 100.0% 100.0%
Estimated uncollectible accounts as a percent of revenues 0.6% 1.1%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 47.3 42.3
Days of revenue outstanding- including unapplied Medicare payments 44.5 34.3

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Market risk

As filed, 572 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2025, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Controls and procedures

As filed, 845 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 1,735 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Significant Tariffs Could Increase Costs, Decrease Margin, and Materially Adversely Affect the Business.

Both Roto-Rooter’s and VITAS’s primary businesses are the provision of services within the United States. Accordingly, they are likely to be less affected by the impact of specific or wide-ranging tariffs than many other entities in the United States and Global economies. However, significant tariffs on certain products, such as steel for Roto-Rooter’s cabling machines and pharmaceuticals utilized by VITAS, could materially increase the costs of Roto-Rooter and VITAS. Additionally, because our service businesses heavily rely on delivering service to customers or patients in their residences, increases in the costs of vehicle acquisition, maintenance, repair, and reimbursement for employees’ use of personal vehicles, could have a significant increase on our expenses.

These additional costs, in the case of VITAS, cannot be passed along to our patients because of the structure of hospice reimbursement, and in the case of Roto-Rooter, may not be able to be fully passed along to our customers. These additional costs could materially adversely affect our margins.

To the extent that tariffs cause any adverse impacts on global supply chains, it could further materially affect the ability of both businesses to timely source critical supplies, which may affect our delivery of services.

If, as a result of tariffs, the United States’ economy experiences a recession or other economic slowdown, the demand for Roto-Rooter’s non-emergency services may decline materially.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$646.9mus-gaap:Revenues
Cost of revenue3 months2025-01-01 to 2025-03-31$430.5mus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2025-01-01 to 2025-03-31$105.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-01-01 to 2025-03-31$94.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-01-01 to 2025-03-31$329.0kus-gaap:InterestExpense
Income tax3 months2025-01-01 to 2025-03-31$23.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31$71.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31$4.86us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31$4.91us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-3114,764,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31$32.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$13.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2025-01-01 to 2025-03-31$7.3mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases3 months2025-01-01 to 2025-03-31$33.2mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-03-31$173.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$502.4mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$1.73bnus-gaap:Assets
Current liabilitiesAt period end2025-03-31$290.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-03-31$544.8mus-gaap:Liabilities
Shareholders' equityAt period end2025-03-31$1.18bnus-gaap:StockholdersEquity
Shares outstandingAt period end2025-03-3114,629,484 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001562762-25-000096. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.